Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.80 USD
-0.08 (-4.26%)
Updated Sep 20, 2024 03:55 PM ET
After-Market: $1.80 0.00 (0.00%) 6:46 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Actinium Pharmaceuticals, Inc. [ATNM]
Reports for Purchase
Showing records 21 - 40 ( 97 total )
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q23 Results; Radiotherapy Portfolio Shows No Signs of Slowing Down; Iomab-B BLA Submission Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
CD33- and HER3-Targeting Radiotherapeutics Reveal Preclinical Efficacy in Multiple Solid Tumor Models
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2022 Results; Key Regulatory Milestones Ahead; BLA Submission For Iomab-B Expected 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
KOL Call Highlights Importance of Iomab-B For Addressing Advanced r/r AML and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Thank You SIERRA; Active r/r AML Patients Could Have New Meaningful Option; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Broad CRADA With NCI Shines Bright Light on Actimab- A; Major Cost Savings Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A / CLAG-M Combination Data Don''t Disappoint at ASH; Full Positive SIERRA Data Likely Early 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q22 Results; Full Data Looks From SIERRA and Actimab-A/CLAG Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A / CLAG-M r/rAML Study Shows Important Survival Benefit in Tough Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Happy Monday with p<0.0001; SIERRA Hits Big; Price Target Increased to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Huge 4Q Ahead While Cash Strong; SIERRA Data Very Close
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Time to Step Up for These Catalysts; Making Real Differences
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q22 Results; Clinical and Regulatory Milestones Remain On Track; SIERRA Top-Line Data By Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q22 Results; Clinical and Regulatory Milestones Remain On Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q22 Results; Cash to Mid-2025; Our SIERRA Confidence Remains High For Positive Readout Later This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Another Confidence Boost From SIERRA As We Project Positive Outcome in 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
AACR Data Support Early Anti-Tumor Activity of HER3-Targeted Radiotherapy; Positive Efficacy Solo and in Combo
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Radiopharma Gets Another Boost; Iomab-B Partnered in EUMENA; SIERRA Top-Line Data in 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2021 Results; SIERRA Prepped for 3Q22 Data and Projected Major Inflection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reasons to Sit Down with These Healthcare/Biotech Management
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E